Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MESO 
Mesoblast Ltd (MESO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: MESO (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $35
1 Year Target Price $35
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 454.74% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.94B USD | Price to earnings Ratio - | 1Y Target Price 35 |
Price to earnings Ratio - | 1Y Target Price 35 | ||
Volume (30-day avg) 3 | Beta 0.76 | 52 Weeks Range 9.61 - 22.00 | Updated Date 11/22/2025 |
52 Weeks Range 9.61 - 22.00 | Updated Date 11/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date 2025-11-26 | When - | Estimate -0.1 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -302.37% |
Management Effectiveness
Return on Assets (TTM) -5.37% | Return on Equity (TTM) -18.95% |
Valuation
Trailing PE - | Forward PE 454.55 | Enterprise Value 2092079645 | Price to Sales(TTM) 128.69 |
Enterprise Value 2092079645 | Price to Sales(TTM) 128.69 | ||
Enterprise Value to Revenue 123.25 | Enterprise Value to EBITDA -6.55 | Shares Outstanding 128293480 | Shares Floating 777251671 |
Shares Outstanding 128293480 | Shares Floating 777251671 | ||
Percent Insiders 5.09 | Percent Institutions 2.54 |
Upturn AI SWOT
Mesoblast Ltd
Company Overview
History and Background
Mesoblast Ltd, founded in 2004, is an Australian regenerative medicine company focused on developing and commercializing cellular medicines to treat inflammatory conditions. It has evolved from a research-focused entity to a clinical-stage company with several late-stage product candidates.
Core Business Areas
- Segment Name 1: Allogeneic Cellular Medicines: Develops and commercializes 'off-the-shelf' cellular therapies for inflammatory conditions.
- Segment Name 2: Remestemcel-L: Lead product candidate focused on treating steroid-refractory acute graft versus host disease (sr-aGVHD).
Leadership and Structure
The company is led by a management team with expertise in regenerative medicine and biopharmaceutical development. The organizational structure includes research and development, clinical operations, and commercialization divisions.
Top Products and Market Share
Key Offerings
- Product Name 1: Remestemcel-L (Ryoncil): Cell therapy candidate for sr-aGVHD. While approved in Japan, it's yet to secure FDA approval in the US. Competitors include Incyte's Jakafi (INCY).
- Product Name 2: MPC-150-IM: Cell therapy candidate for chronic heart failure. This has not yet been launched into the market. Competitors depend on the outcome of clinical trials
Market Dynamics
Industry Overview
The regenerative medicine industry is experiencing rapid growth, driven by advancements in cell therapy and gene therapy. There's increasing demand for therapies addressing unmet needs in inflammatory and degenerative diseases.
Positioning
Mesoblast is positioned as a key player in the allogeneic cell therapy space, with a focus on innovative treatments for inflammatory conditions. Its competitive advantage lies in its proprietary cell manufacturing platform and late-stage clinical pipeline.
Total Addressable Market (TAM)
The TAM for regenerative medicine is estimated to be in the tens of billions USD annually. Mesoblast targets specific niches within this TAM, such as sr-aGVHD. The success of Remestemcel-L's approval determines Mesoblast's position with respect to this TAM.
Upturn SWOT Analysis
Strengths
- Proprietary cell therapy platform
- Late-stage clinical pipeline
- Established manufacturing capabilities
- Strategic partnerships
Weaknesses
- Regulatory approval challenges (FDA)
- Cash burn rate
- Commercialization risks
- Dependence on key products
Opportunities
- Expanding indications for existing product candidates
- Strategic collaborations and acquisitions
- Geographic expansion
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- INCY
- BMY
- JNJ
Competitive Landscape
Mesoblast faces competition from established pharmaceutical companies with broader product portfolios. Its advantages include its allogeneic cell therapy platform. Its disadvantage is that it has not received regulatory approval from the FDA.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial advancements and partnership agreements. This has been volatile
Future Projections: Future growth depends on successful FDA approval of Remestemcel-L, expanding into new indications, and securing additional partnerships.
Recent Initiatives: Recent initiatives include seeking regulatory approval for Remestemcel-L in the US and progressing clinical trials for other product candidates.
Summary
Mesoblast is a regenerative medicine company with an innovative cell therapy platform. Securing FDA approval for Remestemcel-L and managing cash burn are critical. The company holds potential if approval comes and successful clinical trials continue. Strong competition in the biopharmaceutical landscape poses a significant challenge.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. It is based on publicly available information and analyst estimates, which are subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mesoblast Ltd
Exchange NASDAQ | Headquaters Melbourne, VIC, Australia | ||
IPO Launch date 2015-11-13 | Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | ||
Sector Healthcare | Industry Biotechnology | Full time employees 81 | Website https://www.mesoblast.com |
Full time employees 81 | Website https://www.mesoblast.com | ||
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.